- Home
- BCYC vs ATXS Comparison
BCYC vs ATXS Comparison
Compare BCYC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- ATXS
- Stock Information
- Founded
- BCYC 2009
- ATXS 2008
- Country
- BCYC United Kingdom
- ATXS United States
- Employees
- BCYC N/A
- ATXS N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- BCYC Health Care
- ATXS Health Care
- Exchange
- BCYC Nasdaq
- ATXS Nasdaq
- Market Cap
- BCYC 492.1M
- ATXS 424.4M
- IPO Year
- BCYC 2019
- ATXS 2015
- Fundamental
- Price
- BCYC $6.92
- ATXS $7.39
- Analyst Decision
- BCYC Buy
- ATXS Buy
- Analyst Count
- BCYC 11
- ATXS 6
- Target Price
- BCYC $22.91
- ATXS $33.00
- AVG Volume (30 Days)
- BCYC 213.9K
- ATXS 337.6K
- Earning Date
- BCYC 10-30-2025
- ATXS 11-12-2025
- Dividend Yield
- BCYC N/A
- ATXS N/A
- EPS Growth
- BCYC N/A
- ATXS N/A
- EPS
- BCYC N/A
- ATXS N/A
- Revenue
- BCYC $19,281,000.00
- ATXS N/A
- Revenue This Year
- BCYC N/A
- ATXS N/A
- Revenue Next Year
- BCYC N/A
- ATXS N/A
- P/E Ratio
- BCYC N/A
- ATXS N/A
- Revenue Growth
- BCYC N/A
- ATXS N/A
- 52 Week Low
- BCYC $6.10
- ATXS $3.56
- 52 Week High
- BCYC $28.67
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- BCYC 41.28
- ATXS 57.24
- Support Level
- BCYC $6.77
- ATXS $6.99
- Resistance Level
- BCYC $7.32
- ATXS $7.94
- Average True Range (ATR)
- BCYC 0.39
- ATXS 0.51
- MACD
- BCYC 0.01
- ATXS 0.02
- Stochastic Oscillator
- BCYC 19.04
- ATXS 70.46
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.